期刊文献+

奥氮平与利培酮治疗精神分裂症所致代谢综合征对照研究 被引量:14

A control of schizophrenia ’ s metabolic syndrome caused by olanzapine and risperidone
下载PDF
导出
摘要 目的:探讨奥氮平与利培酮治疗精神分裂症导致代谢综合征的发生状况。方法将86例精神分裂症患者随机分成两组,分别口服奥氮平及利培酮治疗,观察12周。于治疗前后采用阳性与阴性症状量表评定精神症状,同时检测血压、身高、体质量、腰围及空腹血糖、血脂水平的变化。结果治疗后两组阳性与阴性症状量表评分均较治疗前显著下降( P<0.05或0.01),治疗各时段两组评分比较差异均无显著性(P>0.05)。治疗后两组体质量及体质量指数均较治疗前显著增加,空腹血糖、三酰甘油、总胆固醇、低密度脂蛋白水平均较治疗显著升高,高密度脂蛋白较治疗前显著下降,治疗8周末起差异均有显著性( P<0.05或0.01);同期两组间各项指标比较差异均无显著性( P>0.05)。治疗12周末两组腰围超标,空腹血糖、三酰甘油、总胆固醇、低密度脂蛋白水平升高,高密度脂蛋白水平降低,代谢综合征检出率比较差异均无显著性(P>0.05)。结论奥氮平与利培酮治疗精神分裂症疗效相当,但对患者的糖脂代谢均有不同程度的影响,均存在发生代谢综合征的风险,临床治疗中应密切监视各项代谢指标的变化。 Objective To explore schizophrenia’s metabolic syndromes caused by olanzapine and risperi-done .Methods Eighty-six schizophrenics were randomly assigned to two groups taking orally olanzapine or risperidone for 12 weeks .Mental symptoms were assessed with the Positive and Negative Syndrome Scale (PANSS) before and after treatment and changes of BP ,body height (BH) ,body mass (BM) ,waist circumference (WC) ,fasting blood sugar (FBS) and blood fit (BF) detected simultaneously .Results Af-ter treatment the PANSS scores of both groups lowered more significantly compared with pretreatment (P〈0 .05 or 0 .01) ,those had no significant group differences in each period of treatment (P〉0 .05) .Af-ter treatment BM and BMI of both groups increased more significantly ,FBS ,triacylglycerol ,total choles-terol (TC) ,LDL levels heightened and HDL lowered ,and differences had significances since the end of the 8th week (P〈0 .05 or 0 .01) .In the corresponding period all indexes had no significant group differences (P〉0 .05) .There were no significant group differences in over-standard WC ,the elevation of FBS ,tria-cylglycerol .TC and LDL ,the reduction of HDL and the detection rate of metabolic syndrome (P〉0 .05) . Conclusion Olanzapine and risperidone have therapeutic equivalence in schizophrenia ,different influences on patients’ glucose and lipid metabolism and the risk of causing metabolic syndromes ,so clinically all metabolic indexes should be closely watched .
出处 《临床心身疾病杂志》 CAS 2014年第5期1-4,共4页 Journal of Clinical Psychosomatic Diseases
关键词 精神分裂症 奥氮平 利培酮 代谢综合征 代谢性疾病 血糖 血脂 体质量 Schizophrenia olanzapine risperidone metabolic syndrome metabolic disease blood sugar blood fat body mass
  • 相关文献

参考文献14

二级参考文献100

共引文献626

同被引文献160

  • 1阎得胜,闫可域,祁婧,权伟.老年患者341例抗精神病用药分析[J].陕西医学杂志,2020,49(3):337-340. 被引量:8
  • 2孙霞,刘健.非典型抗精神病药物与传统抗精神病药物对肝脏转氨酶的影响[J].国际中华神经精神医学杂志,2005,6(1):42-43. 被引量:3
  • 3程艮,李峥.精神分裂症患者药物依从性影响因素的研究进展[J].中华护理杂志,2005,40(9):699-701. 被引量:59
  • 4汪向东 王希林 马弘.心理卫生评定量表手册.中国心理卫生杂志,1999,12:217-217.
  • 5Newcomer JW.Second-generation(atypical)antipsychotics and metabolic effects[J].CNS drugs,2005,19:1-93.
  • 6Simpson GM.Atypical anti-psychotics and the burden of disease[J].Am J Manag Care,2005,11:235-241.
  • 7Rena G,Pearson ER,Sakamoto K.Molecular mechanism of action of metformin:old or new insights?[J].Diabetologia,2013,56:1898-1906.
  • 8Lu J,Ji J,Meng H,et al.The protective effect and underlying mechanism of metformin on neointima formation in fructose-induced insulin resistant rats[J].Cardiovasc Diabetol,2013,12:58-64.
  • 9Henderson DC, Sharma B, Fan X, et al. Dietary satu- rated fat intake and glucose metabolism impairments in non diabetic, nonobese patients with schizophrenia on clozapine or risperidone [J]. Ann Clin Psychiatry, 2010,22 ( 1 ) : 33.
  • 10Chiliza B, Asmal IJ, Oosthuizen P. Changes in body mass and metabolic profiles in patients with first episode schizophrenia treated for 12 months with a first-generation antipsychotic [J]. Eur Psychiatry, 2015,30 ( 2 ) : 277.

引证文献14

二级引证文献95

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部